RE: REAT20 Apr 2020 14:01
The only thing React has in common with them is that its earnings will benefit from Covid-19. Fortunately, it carries far less risk than a pharma/biotech (NYCT) and medical devices company (ODX, GDR). That said, all of them could do very well.
Still, let's not quibble. It certainly should get regular repeat business. Moreover, it is scaling up. Not sure to what extent this partnering move is a franchise (does it supply materials and training? What are the exact terms?) but it certainly gives more scale as REACT has only 90 employees.